Tiwari Ashutosh, Ika Krisnawati Dyah, Susilowati Erna, Mutalik Chinmaya, Kuo Tsung-Rong
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Department of Nursing, Faculty of Nursing and Midwifery, Universitas Nahdlatul Ulama Surabaya, Surabaya, 60237 East Java, Indonesia.
J Agric Food Chem. 2024 Dec 18;72(50):27679-27700. doi: 10.1021/acs.jafc.4c08702. Epub 2024 Nov 26.
The burgeoning field of microbiome research has profoundly reshaped our comprehension of human health, particularly highlighting the potential of probiotics and fecal microbiota transplantation (FMT) as therapeutic interventions. While the benefits of traditional probiotics are well-recognized, the efficacy and mechanisms remain ambiguous, and FMT's long-term effects are still being investigated. Recent advancements in high-throughput sequencing have identified gut microbes with significant health benefits, paving the way for next-generation probiotics (NGPs). These NGPs, engineered through synthetic biology and bioinformatics, are designed to address specific disease states with enhanced stability and viability. This review synthesizes current research on NGP stability, challenges in delivery, and their applications in preventing and treating chronic diseases such as diabetes, obesity, and cardiovascular diseases. We explore the physiological characteristics, safety profiles, and mechanisms of action of various NGP strains while also addressing the challenges and opportunities presented by their integration into clinical practice. The potential of NGPs to revolutionize microbiome-based therapies and improve clinical outcomes is immense, underscoring the need for further research to optimize their efficacy and ensure their safety.
微生物组研究这一新兴领域已深刻重塑了我们对人类健康的理解,尤其凸显了益生菌和粪便微生物群移植(FMT)作为治疗干预手段的潜力。虽然传统益生菌的益处已得到广泛认可,但其功效和作用机制仍不明确,FMT的长期影响仍在研究中。高通量测序技术的最新进展已鉴定出对健康有显著益处的肠道微生物,为下一代益生菌(NGP)的发展铺平了道路。这些通过合成生物学和生物信息学设计的NGP旨在以更高的稳定性和活力应对特定疾病状态。本综述综合了当前关于NGP稳定性、递送挑战及其在预防和治疗糖尿病、肥胖症和心血管疾病等慢性病方面应用的研究。我们探讨了各种NGP菌株的生理特性、安全性概况和作用机制,同时也讨论了将其整合到临床实践中所面临的挑战和机遇。NGP彻底改变基于微生物组的疗法并改善临床结果的潜力巨大,这突出表明需要进一步研究以优化其疗效并确保其安全性。